Join Growin Stock Community!

Apollomics, inc.APLM.US Overview

US StockHealthcare
(No presentation for APLM)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

APLM AI Insights

APLM Overall Performance

APLM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

APLM Recent Performance

-1.97%

Apollomics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

APLM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

APLM Key Information

APLM Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

APLM Profile

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

Price of APLM

APLM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

APLM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-53.62
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
6.25
PB Ratio
8.15
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-85.79%
Net Margin
-1293.25%
Revenue Growth (YoY)
53.27%
Profit Growth (YoY)
-231.49%
3-Year Revenue Growth
409.39%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-53.62
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
6.25
PB Ratio
8.15
Price-to-FCF
-
Gross Margin
-85.79%
Net Margin
-1293.25%
Revenue Growth (YoY)
53.27%
Profit Growth (YoY)
-231.49%
3-Year Revenue Growth
409.39%
3-Year Profit Growth
-100.00%

  • When is APLM's latest earnings report released?

    The most recent financial report for Apollomics, inc. (APLM) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating APLM's short-term business performance and financial health. For the latest updates on APLM's earnings releases, visit this page regularly.

  • What is the operating profit of APLM?

    According to the latest financial report, Apollomics, inc. (APLM) reported an Operating Profit of -10.61M with an Operating Margin of -124.8% this period, representing a growth of 58.09% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is APLM's revenue growth?

    In the latest financial report, Apollomics, inc. (APLM) announced revenue of 8.5M, with a Year-Over-Year growth rate of 380.77%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does APLM have?

    As of the end of the reporting period, Apollomics, inc. (APLM) had total debt of 744K, with a debt ratio of 0.07. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does APLM have?

    At the end of the period, Apollomics, inc. (APLM) held Total Cash and Cash Equivalents of 2.09M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is APLM's EPS continuing to grow?

    According to the past four quarterly reports, Apollomics, inc. (APLM)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -11.37. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.